What this page establishes
- FDA approved orforglipron (Foundayo) on 1 April 2026 for chronic weight management under NDA 220934, with six tablet strengths to a maximum of 17.2 mg once daily.
- Orforglipron produced 12.4% mean weight loss at 72 weeks on the efficacy estimand in its registration programme, ATTAIN-1 (NCT05869903, 3,127 participants) and ATTAIN-2 (NCT05872620, 1,613 participants), both placebo-controlled.
- No published randomised trial compares orforglipron directly with semaglutide or tirzepatide.
- Wegovy carries a cardiovascular risk reduction indication in adults with established cardiovascular disease and obesity or overweight. Foundayo carries no cardiovascular outcome indication.
Quick answers
Is Foundayo as effective as Wegovy?
Unknown, and not in a coy way: no trial has compared them. Orforglipron produced 12.4% mean weight loss at 72 weeks against placebo.
Read the full answer
Wegovy’s numbers come from a separate programme in a different population. Comparing across trials is not a comparison.Is a tablet worse than an injection?
Not inherently. Orforglipron is a small molecule rather than a peptide, so it survives digestion without the workarounds oral semaglutide needs, and it is taken with or without food.
Read the full answer
The open question is efficacy against the injectables, not whether tablets can work.Can I take Foundayo with another GLP-1?
The label says concomitant use with another GLP-1 receptor agonist is not recommended.
Read the full answer
Foundayo is orforglipron, approved on 1 April 2026, and it is the first small-molecule GLP-1 receptor agonist licensed for weight. That matters because it is not a peptide, so it works as an ordinary daily tablet with no absorption workaround. The obvious question is how it compares with Wegovy. Nobody has run that trial.
Why the tablet changes more than convenience
Every other weight brand in this class is a peptide, which is why they are injected, and why the one oral peptide product needs to be taken on an empty stomach with a sip of water under strict conditions.
Orforglipron is a small molecule. It is taken once daily with or without food. That removes the dosing ritual entirely, and it also changes what manufacturing at scale looks like, which is the part of this that affects supply rather than physiology.
There is no head-to-head, and that is a finding
ATTAIN-1 (NCT05869903, 3,127 participants) and ATTAIN-2 (NCT05872620, 1,613 participants) are the registration trials, and both are placebo-controlled. No active-comparator trial of orforglipron against semaglutide or tirzepatide has been published.
So the comparison that would answer the question does not exist yet. Foundayo produced 12.4% mean weight loss at 72 weeks on the efficacy estimand in its own programme, and Wegovy’s figures come from a different programme in a different population. Setting those two numbers beside each other and declaring a winner is exactly the move this site does not make.
What the labels say
Foundayo is licensed with a reduced-calorie diet and increased physical activity for long-term weight reduction in adults with obesity, or overweight with at least one weight-related condition. Six tablet strengths run 0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg once daily. Its label states that concomitant use with another GLP-1 receptor agonist is not recommended.
Wegovy covers the same weight population plus children aged 12 and over, and adds a cardiovascular risk reduction indication in established cardiovascular disease. Foundayo has no cardiovascular outcome indication.
Both carry a boxed warning for thyroid C-cell tumours, and both are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.
The evidence, one row per claim
| Claim | Tier | Source |
|---|---|---|
| FDA approved orforglipron (Foundayo) on 1 April 2026 for chronic weight management under NDA 220934, with six tablet strengths to a maximum of 17.2 mg once daily. | established | FDA Structured Product Label, NDA220934 (via openFDA) |
| Orforglipron produced 12.4% mean weight loss at 72 weeks on the efficacy estimand in its registration programme, ATTAIN-1 (NCT05869903, 3,127 participants) and ATTAIN-2 (NCT05872620, 1,613 participants), both placebo-controlled. | established | ClinicalTrials.gov, ATTAIN-1; site regulatory verification 2026-08-23 |
| No published randomised trial compares orforglipron directly with semaglutide or tirzepatide. | established | ClinicalTrials.gov search, confirmed absence 2026-08-30 |
| Wegovy carries a cardiovascular risk reduction indication in adults with established cardiovascular disease and obesity or overweight. Foundayo carries no cardiovascular outcome indication. | established | FDA Structured Product Label, NDA215256 (via openFDA) |
Questions people ask
Does Foundayo have a heart indication like Wegovy?
No. Wegovy carries a cardiovascular risk reduction indication for established cardiovascular disease with obesity or overweight. Foundayo’s label covers weight only.
Sources
- FDA Structured Product Label, NDA220934 (via openFDA)
- ClinicalTrials.gov, ATTAIN-1; site regulatory verification 2026-08-23
- FDA Structured Product Label, NDA215256 (via openFDA)
Keep reading
- Wegovy vs Zepbound: The Head-to-Head Trial, and What It MeasuredMost brand comparisons infer from separate trials. This one has a randomised head-to-head, which makes it the
- Ozempic vs Mounjaro: The Diabetes Head-to-HeadBoth are licensed for diabetes, and unusually for this category there is a randomised trial of one against the